AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20585051 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 0
Study 18506129 — intervention group
Group type: EXPERIMENTAL
Intervention: Propionyl-L-carnitine (PLC) therapy at a dosage of 1,200 mg PLC in 250 cc of physiological solution for 5 days a week for 4 weeks
Number of subjects: 42
Study 18506129 — intervention group
Group type: EXPERIMENTAL
Intervention: Propionyl-L-carnitine (PLC) in association with pulsed muscular compression therapy (Vascupump) for 5 sessions a week for 4 weeks
Number of subjects: 42
Study 18506129 — intervention group
Group type: COMPARATOR
Intervention: Pulsed muscular compression therapy (Vascupump) only
Number of subjects: 42
Study 18506129 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life questionnaire
Number of subjects: 42
Study 18506129 — intervention group
Group type: EXPERIMENTAL
Intervention: Instrumental parameters (CT and Winsor index)
Number of subjects: 42
Study 15898936 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic amoxicillin plus metronidazole and CHX irrigation
Number of subjects: 35
Study 15898936 — intervention group
Group type: COMPARATOR
Intervention: Subgingival scaling without adjunctive therapy (control group)
Number of subjects: 35
Study 12918613 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-linear amplification with fast time constants
Number of subjects: 50
Study 12918613 — intervention group
Group type: EXPERIMENTAL
Intervention: Amplified condition
Number of subjects: 50
Study 12918613 — intervention group
Group type: COMPARATOR
Intervention: Unaided condition
Number of subjects: 50
Study 10497771 — intervention group
Group type: EXPERIMENTAL
Intervention: Cover gowns and shoe covers worn by caregivers
Number of subjects: 40
Study 10497771 — intervention group
Group type: COMPARATOR
Intervention: No covers worn by caregivers
Number of subjects: 40
Study 8983866 — intervention group
Group type: EXPERIMENTAL
Intervention: High fat meal with insulin (peak insulin 86.1 ± 10.1 m-units/l)
Number of subjects: 9
Study 8983866 — intervention group
Group type: COMPARATOR
Intervention: High fat meal alone
Number of subjects: 9
Study 1682521 — intervention group
Group type: EXPERIMENTAL
Intervention: Apraclonidine hydrochloride
Number of subjects: 20
Study 1682521 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 6959168 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of methadone
Number of subjects: 9
Study 6959168 — intervention group
Group type: COMPARATOR
Intervention: Inert placebo
Number of subjects: 9
Study 31881956 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided-care
Number of subjects: 1541
Study 31881956 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided-care (with gene-drug interactions)
Number of subjects: 1541
Study 31881956 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 1541
Study 29417694 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine (DLX, 60 mg once daily)
Number of subjects: 39
Study 29417694 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 26460570 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (NAL)
Number of subjects: 165
Study 26460570 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (NAL) and prolonged exposure (PE)
Number of subjects: 165
Study 26460570 — intervention group
Group type: COMPARATOR
Intervention: Pill placebo
Number of subjects: 165
Study 26460570 — intervention group
Group type: COMPARATOR
Intervention: Pill placebo and PE
Number of subjects: 165
Study 25077896 — intervention group
Group type: EXPERIMENTAL
Intervention: Active cuff management during cooling and warming (cuff pressure monitored and adjusted)
Number of subjects: 24
Study 25077896 — intervention group
Group type: COMPARATOR
Intervention: Passive monitoring (cuff pressure monitored but not adjusted)
Number of subjects: 24
Study 25077896 — intervention group
Group type: EXPERIMENTAL
Intervention: Active cuff management
Number of subjects: 24
Study 25077896 — intervention group
Group type: COMPARATOR
Intervention: Passive monitoring
Number of subjects: 24
Study 22689187 — intervention group
Group type: EXPERIMENTAL
Intervention: Totally thoracoscopic repair of VSDs
Number of subjects: 36
Study 22689187 — intervention group
Group type: COMPARATOR
Intervention: Traditional VSD closure through sternotomy
Number of subjects: 36
Study 19719472 — intervention group
Group type: EXPERIMENTAL
Intervention: WBC‐kit
Number of subjects: 68
Study 19719472 — intervention group
Group type: COMPARATOR
Intervention: AUTO‐kit
Number of subjects: 68
Study 18590940 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-week arginine, proline, glutamate and aspartate-free diet (APF diet)
Number of subjects: 10
Study 18590940 — intervention group
Group type: COMPARATOR
Intervention: Complete amino acid diet (control diet)
Number of subjects: 10
Study 15801505 — intervention group
Group type: EXPERIMENTAL
Intervention: Elaborated words (treatment group)
Number of subjects: 57
Study 15801505 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-elaborated words (treatment group)
Number of subjects: 57
Study 15801505 — intervention group
Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 57
Study 12616734 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine (FL)
Number of subjects: 60
Study 12616734 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline (AM)
Number of subjects: 60
Study 10393518 — intervention group
Group type: EXPERIMENTAL
Intervention: Tretinoin emollient cream, 0.05% (Renova) used nightly in conjunction with daytime usage of one of two 8% glycolic acid lotions.
Number of subjects: 0
Study 10393518 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant use of effective moisturizers, mild cleansers, and daily sunscreens with tretinoin.
Number of subjects: 0
Study 8879766 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to cytomegalovirus (CMV) from the donated organ
Number of subjects: 146
Study 8879766 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with bacteremia
Number of subjects: 146
Study 8879766 — intervention group
Group type: COMPARATOR
Intervention: Patients without bacteremia
Number of subjects: 146
Study 8879766 — intervention group
Group type: EXPERIMENTAL
Intervention: Donor CMV seropositivity
Number of subjects: 146
Study 8879766 — intervention group
Group type: EXPERIMENTAL
Intervention: Age younger than 16 years
Number of subjects: 146
Study 8879766 — intervention group
Group type: EXPERIMENTAL
Intervention: Major abdominal operation after transplantation (excluding retransplantation)
Number of subjects: 146
Study 1991685 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined modality (CM) treatment with Cisplatin 50 mg IV weekly during radiotherapy.
Number of subjects: 83
Study 1991685 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy (RT) without chemotherapy.
Number of subjects: 83
Study 6663643 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured couples treatment program
Number of subjects: 20
Study 6663643 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 20
Study 31430249 — intervention group
Group type: EXPERIMENTAL
Intervention: Limited sampling strategy (LSS) for estimating AUC0-12 of mycophenolic acid (MPA)
Number of subjects: 45
Study 31430249 — intervention group
Group type: EXPERIMENTAL
Intervention: Limited sampling strategy (LSS) for estimating AUC0-12 of acyl glucuronide metabolite (AcMPAG)
Number of subjects: 45
Study 29570535 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone supplementation with testosterone enanthate injections at 2-week intervals during bed rest
Number of subjects: 0
Study 29570535 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized aerobic and resistance training 6 days per week in a horizontal body position
Number of subjects: 0
Study 29570535 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized measures targeting a wide range of physiologic systems
Number of subjects: 0
Study 29570535 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized diet provided to ensure consistent nutritional intake
Number of subjects: 0
Study 29570535 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily measurements of vital signs, body weight, and fluid intake and output
Number of subjects: 0
Study 28931527 — intervention group
Group type: EXPERIMENTAL
Intervention: e‐cigarette with nicotine
Number of subjects: 33
Study 28931527 — intervention group
Group type: EXPERIMENTAL
Intervention: e‐cigarette without nicotine
Number of subjects: 33
Study 28931527 — intervention group
Group type: COMPARATOR
Intervention: sham control
Number of subjects: 33
Study 26239595 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep neuromuscular blockade (NMB)
Number of subjects: 34
Study 26239595 — intervention group
Group type: COMPARATOR
Intervention: No neuromuscular blockade (NMB)
Number of subjects: 34
Study 22075412 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stents (PES)
Number of subjects: 800
Study 22075412 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 800
Study 21632697 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% icodextrin solution (Adept)
Number of subjects: 498
Study 21632697 — intervention group
Group type: COMPARATOR
Intervention: Lactated Ringer's solution (LRS)
Number of subjects: 498
Study 18292445 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative celecoxib (2 celecoxib 200 mg p.o. after surgery, followed by one celecoxib 200 mg p.o. BID on postoperative day #1, #2 and #3)
Number of subjects: 120
Study 18292445 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative celecoxib (2 celecoxib 200 mg p.o. 30‐90 min before surgery, and two placebos after surgery, followed by one celecoxib 200 mg p.o. BID on postoperative day #1, #2, and #3)
Number of subjects: 120
Study 18292445 — intervention group
Group type: COMPARATOR
Intervention: Control group (two placebos orally before and after surgery, as well as one placebo BID for 3 days after surgery)
Number of subjects: 120
Study 16548286 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine administered prior to anesthesia
Number of subjects: 3
Study 16548286 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine administered during transanesthesia
Number of subjects: 3
Study 16548286 — intervention group
Group type: COMPARATOR
Intervention: Control group (no dexmedetomidine)
Number of subjects: 3
Study 12656882 — intervention group
Group type: EXPERIMENTAL
Intervention: beta-tricalciumphosphate (beta-TCP) with platelet-rich plasma (PRP)
Number of subjects: 39
Study 12656882 — intervention group
Group type: COMPARATOR
Intervention: beta-tricalciumphosphate (beta-TCP) without platelet-rich plasma (PRP)
Number of subjects: 39
Study 11191783 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid replacement (200 or 250 ml of warm water at approximately 35 degrees C) during light exercise (L/F)
Number of subjects: 8
Study 11191783 — intervention group
Group type: COMPARATOR
Intervention: No fluid (NF) during light exercise (L/NF)
Number of subjects: 8
Study 11191783 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid replacement (F) during heavy exercise (H)
Number of subjects: 8
Study 11191783 — intervention group
Group type: COMPARATOR
Intervention: No fluid (NF) during heavy exercise (H/NF)
Number of subjects: 8
Study 11191783 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid replacement (F) during light exercise (L)
Number of subjects: 8
Study 11191783 — intervention group
Group type: COMPARATOR
Intervention: No fluid (NF) during light exercise (L)
Number of subjects: 8
Study 11191783 — intervention group
Group type: COMPARATOR
Intervention: No fluid (NF) during heavy exercise (H)
Number of subjects: 8
Study 11191783 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid replacement during light exercise (L/F)
Number of subjects: 8
Study 11191783 — intervention group
Group type: COMPARATOR
Intervention: No fluid during light exercise (L/NF)
Number of subjects: 8
Study 11191783 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid replacement during heavy exercise (H/F)
Number of subjects: 8
Study 11191783 — intervention group
Group type: COMPARATOR
Intervention: No fluid during heavy exercise (H/NF)
Number of subjects: 8
Study 9097062 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient mental health visits to primary care providers
Number of subjects: 391
Study 9097062 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient mental health visits to specialty mental health providers
Number of subjects: 391
Study 9097062 — intervention group
Group type: EXPERIMENTAL
Intervention: Visits to nonpsychiatrist medical specialists
Number of subjects: 391
Study 9097062 — intervention group
Group type: EXPERIMENTAL
Intervention: Service utilization based on frequency of panic attacks
Number of subjects: 391
Study 9097062 — intervention group
Group type: EXPERIMENTAL
Intervention: Service utilization based on severity of impairment
Number of subjects: 391
Study 9097062 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimated expenditure for panic episode
Number of subjects: 391
Study 9097062 — intervention group
Group type: EXPERIMENTAL
Intervention: Median estimated expenditures for primary care and specialty mental health services
Number of subjects: 391
Study 8255440 — intervention group
Group type: EXPERIMENTAL
Intervention: Branched-chain amino acids (BCAA) - L‐leucine 12 g, L‐isoleucine 6 g, L‐valine 6 g daily
Number of subjects: 126
Study 8255440 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study 8255440 — intervention group
Group type: EXPERIMENTAL
Intervention: Branched-chain amino acids (BCAA)
Number of subjects: 126
Study 3515261 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular ritodrine followed by oral ritodrine treatment and bed rest
Number of subjects: 99
Study 3515261 — intervention group
Group type: COMPARATOR
Intervention: Placebo and bed rest
Number of subjects: 99
Study 30157364 — intervention group
Group type: EXPERIMENTAL
Intervention: HSC+LC
Number of subjects: 186
Study 30157364 — intervention group
Group type: COMPARATOR
Intervention: LC
Number of subjects: 186
Study 30157364 — intervention group
Group type: COMPARATOR
Intervention: HSC
Number of subjects: 186
Study 26407878 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl low dose (12 μg/kg)
Number of subjects: 25
Study 26407878 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl moderate dose (24 μg/kg)
Number of subjects: 25
Study 26407878 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (for anaesthesia induction)
Number of subjects: 25
Study 26407878 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 25
Study 25630513 — intervention group
Group type: EXPERIMENTAL
Intervention: tirofiban
Number of subjects: 748
Study 25630513 — intervention group
Group type: COMPARATOR
Intervention: conventional therapy
Number of subjects: 748
Study 23043946 — intervention group
Group type: EXPERIMENTAL
Intervention: hCG
Number of subjects: 234
Study 23043946 — intervention group
Group type: COMPARATOR
Intervention: GnRH
Number of subjects: 234
Study 20379004 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug alteration (DA) group
Number of subjects: 390
Study 20379004 — intervention group
Group type: COMPARATOR
Intervention: Single AA patients
Number of subjects: 390
Study 17943420 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalbuphine (2.5, 5, 10, or 20 mg)
Number of subjects: 304
Study 17943420 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalbuphine (ED(50) estimated at 5.85 mg)
Number of subjects: 304
Study 17943420 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (0.2 or 0.4 mg, ED(50) estimated at 0.5 mg)
Number of subjects: 304
Study 17943420 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalbuphine and Naloxone (in combination)
Number of subjects: 304
Study 15723964 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium chloride (96 mmol/d for 1 week)
Number of subjects: 14
Study 15723964 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium citrate (96 mmol/d for 1 week)
Number of subjects: 14
Study 15723964 — intervention group
Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 14
Study 15723964 — intervention group
Group type: COMPARATOR
Intervention: Comparison of potassium chloride and potassium citrate
Number of subjects: 14
Study 12458845 — intervention group
Group type: EXPERIMENTAL
Intervention: Daunorubicin 0.02% applied subconjunctivally for 3 minutes
Number of subjects: 24
Study 12458845 — intervention group
Group type: COMPARATOR
Intervention: Distilled water applied for 3 minutes
Number of subjects: 24
Study 10624842 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive group focusing on positive aspects of information
Number of subjects: 104
Study 10624842 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative group focusing on negative aspects of information
Number of subjects: 104
Study 10624842 — intervention group
Group type: COMPARATOR
Intervention: Control group focusing on an unrelated disease
Number of subjects: 104
Study 8614916 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid PTA
Number of subjects: 11
Study 8614916 — intervention group
Group type: COMPARATOR
Intervention: Carotid endarterectomy
Number of subjects: 11
Study 2006724 — intervention group
Group type: EXPERIMENTAL
Intervention: midazolam/flumazenil (15 mg midazolam, 0.5 mg flumazenil after 60 min)
Number of subjects: 12
Study 2006724 — intervention group
Group type: COMPARATOR
Intervention: placebo/flumazenil (sodium chloride instead of midazolam, 0.5 mg flumazenil after 60 min)
Number of subjects: 12
Study 2006724 — intervention group
Group type: COMPARATOR
Intervention: placebo/placebo (sodium chloride instead of midazolam and flumazenil)
Number of subjects: 12
Study 397411 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 6
Study 397411 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 31030363 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra treatment
Number of subjects: 75
Study 31030363 — intervention group
Group type: COMPARATOR
Intervention: Standard of care for gout flare
Number of subjects: 75
Study 28878376 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress condition
Number of subjects: 60
Study 28878376 — intervention group
Group type: COMPARATOR
Intervention: Non-stress condition
Number of subjects: 60
Study 24585502 — intervention group
Group type: EXPERIMENTAL
Intervention: Resolute zotarolimus-eluting stents (ZES)
Number of subjects: 1033
Study 24585502 — intervention group
Group type: COMPARATOR
Intervention: Xience V everolimus-eluting stents (EES)
Number of subjects: 1033
Study 23635869 — intervention group
Group type: EXPERIMENTAL
Intervention: Kava (120/240 mg of kavalactones per day)
Number of subjects: 75
Study 23635869 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 17456241 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intervention group (educational programme delivered at baseline)
Number of subjects: 23
Study 17456241 — intervention group
Group type: COMPARATOR
Intervention: Delayed intervention group (educational programme delivered at 6 months)
Number of subjects: 23
Study 14742376 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% levobupivacaine combined with 0.1 mg/h morphine
Number of subjects: 50
Study 14742376 — intervention group
Group type: COMPARATOR
Intervention: 0.1% ropivacaine combined with 0.1 mg/h morphine
Number of subjects: 50
Study 14742376 — intervention group
Group type: COMPARATOR
Intervention: 0.1% ropivacaine
Number of subjects: 50
Study 14742376 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% levobupivacaine
Number of subjects: 50
Study 14742376 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% levobupivacaine and 0.1% ropivacaine
Number of subjects: 50
Study 10783450 — intervention group
Group type: EXPERIMENTAL
Intervention: Emla (2.5% lignocaine and 2.5% prilocaine)
Number of subjects: 10
Study 10783450 — intervention group
Group type: COMPARATOR
Intervention: Lignocaine gel alone
Number of subjects: 10
Study 9073002 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate, 1,000 microg x day‐1 for 6 weeks
Number of subjects: 40
Study 7923728 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinforcing manipulation (RFM)
Number of subjects: 78
Study 7923728 — intervention group
Group type: EXPERIMENTAL
Intervention: Reducing manipulation (RDM)
Number of subjects: 78
Study 3018603 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (10‐20 mg b.i.d.)
Number of subjects: 39
Study 3018603 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined enalapril (10‐20 mg b.i.d.) and hydrochlorothiazide (25‐50 mg b.i.d.)
Number of subjects: 39
Study 31679945 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab alone
Number of subjects: 882
Study 31679945 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab with chemotherapy
Number of subjects: 882
Study 31679945 — intervention group
Group type: COMPARATOR
Intervention: Cetuximab with chemotherapy
Number of subjects: 882
Study 31679945 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 882
Study 31679945 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events leading to death
Number of subjects: 882
Study 30236517 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean nighttime wind turbine noise (WTN) exposure during pregnancy
Number of subjects: 135795
Study 30236517 — intervention group
Group type: EXPERIMENTAL
Intervention: High exposure categories of ≥ 42 dB outdoor WTN or ≥ 15 dB indoor LF WTN
Number of subjects: 135795
Study 27416045 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide foam 2 mg/25 mL twice daily for 2 weeks, then once daily for 4 weeks
Number of subjects: 546
Study 25539654 — intervention group
Group type: EXPERIMENTAL
Intervention: Aclidinium 400 μg twice daily
Number of subjects: 112
Study 25539654 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study 21819487 — intervention group
Group type: EXPERIMENTAL
Intervention: Rasagiline
Number of subjects: 0
Study 21819487 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20112485 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-step manipulation and traction (treatment group)
Number of subjects: 120
Study 20112485 — intervention group
Group type: COMPARATOR
Intervention: Traction (control group)
Number of subjects: 120
Study 17484080 — intervention group
Group type: COMPARATOR
Intervention: Intravenous indomethacin (0.2 mg/kg at 12‐hour intervals)
Number of subjects: 21
Study 17484080 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ibuprofen suspension (10 mg/kg initial dose, followed by two doses of 5 mg/kg each after 24 and 48 hours)
Number of subjects: 21